Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Gilead Sciences Inc
since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Gilead Sciences Inc since year 2005.
(See page 1 of this report.) Table 2 shows the detailed insider transactions of Gilead Sciences Inc since 2005.
The reporting company's ticker symbol is GILD. The reporting company's CIK number is 882095.
The total value of stock buying since 2005 is $2,912,783.
The total value of stock sales since 2005 is $2,410,459,518.
The total value of stock option exercises since 2005 is $464,478,779.
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2007-10-25 | Berg Paul | Sale | 6,500 | 44.75 | 290,875 |
| 2007-10-25 | Berg Paul | Option Ex | 10,000 | 2.39 | 23,900 |
| 2007-10-23 | Davignon Etienne | Sale | 35,000 | 42.61 | 1,491,350 |
| 2007-10-09 | Young Kevin (EVP, Commercial Operations) | Sale | 30,000 | 41.57 | 1,246,980 |
| 2007-10-09 | Young Kevin (EVP, Commercial Operations) | Option Ex | 30,000 | 16.84 | 505,259 |
| 2007-10-09 | Martin John C (President and CEO) | Buy | 10,000 | 41.84 | 418,400 |
| 2007-10-09 | Martin John C (President and CEO) | Sale | 60,000 | 41.75 | 2,505,240 |
| 2007-10-09 | Martin John C (President and CEO) | Option Ex | 70,000 | 2.54 | 177,730 |
| 2007-09-12 | Berg Paul | Sale | 13,000 | 37.92 | 492,921 |
| 2007-09-12 | Berg Paul | Option Ex | 13,000 | 2.39 | 31,070 |
| 2007-09-11 | Davignon Etienne | Option Ex | 80,000 | 2.39 | 191,200 |
| 2007-09-11 | Martin John C (President and CEO) | Sale | 70,000 | 37.94 | 2,655,590 |
| 2007-09-11 | Martin John C (President and CEO) | Option Ex | 70,000 | 1.43 | 100,030 |
| 2007-09-07 | Moore Gordon Earle | Option Ex | 144,000 | 2.39 | 344,160 |
| 2007-09-04 | Milligan John F (COO and CFO) | Sale | 60,000 | 36.70 | 2,201,700 |
| 2007-09-04 | Milligan John F (COO and CFO) | Option Ex | 60,000 | 6.74 | 404,580 |
| 2007-08-08 | Denny James M | Sale | 60,000 | 37.81 | 2,268,528 |
| 2007-08-08 | Denny James M | Option Ex | 80,000 | 4.28 | 342,640 |
| 2007-07-11 | Berg Paul | Sale | 13,000 | 39.69 | 515,983 |
| 2007-07-11 | Berg Paul | Option Ex | 13,000 | 2.39 | 31,070 |
| 2007-07-10 | Martin John C (President and CEO) | Sale | 70,000 | 39.66 | 2,776,060 |
| 2007-07-10 | Martin John C (President and CEO) | Option Ex | 70,000 | 1.43 | 100,030 |
| 2007-07-03 | Young Kevin (EVP, Commercial Operations) | Sale | 30,000 | 39.36 | 1,180,830 |
| 2007-07-03 | Young Kevin (EVP, Commercial Operations) | Option Ex | 30,000 | 16.84 | 505,259 |
| 2007-07-02 | Alton Gregg H (SVP, General Counsel) | Sale | 9,500 | 39.32 | 373,568 |
| 2007-07-02 | Alton Gregg H (SVP, General Counsel) | Option Ex | 9,500 | 8.22 | 78,071 |
| 2007-06-12 | Martin John C (President and CEO) | Sale | 35,000 | 78.92 | 2,762,060 |
| 2007-06-12 | Martin John C (President and CEO) | Option Ex | 35,000 | 2.86 | 100,065 |
| 2007-06-04 | Milligan John F (COO and CFO) | Sale | 30,000 | 82.66 | 2,475,640 |
| 2007-06-04 | Milligan John F (COO and CFO) | Option Ex | 30,000 | 9.81 | 294,300 |
| 2007-06-01 | Alton Gregg H (SVP, General Counsel) | Sale | 4,750 | 83.31 | 395,736 |
| 2007-06-01 | Alton Gregg H (SVP, General Counsel) | Option Ex | 4,750 | 16.44 | 78,075 |
| 2007-05-21 | Wilson Gayle E | Sale | 80,250 | 82.90 | 6,648,801 |
| 2007-05-21 | Wilson Gayle E | Option Ex | 180,250 | 37.40 | 6,740,809 |
| 2007-05-09 | Berg Paul | Sale | 6,500 | 83.10 | 540,124 |
| 2007-05-09 | Berg Paul | Option Ex | 6,500 | 4.78 | 31,076 |
| 2007-05-09 | Denny James M | Sale | 30,000 | 83.21 | 2,496,210 |
| 2007-05-09 | Denny James M | Option Ex | 40,000 | 6.76 | 270,600 |
| 2007-05-08 | Martin John C (President and CEO) | Sale | 35,000 | 82.14 | 2,874,865 |
| 2007-05-08 | Martin John C (President and CEO) | Option Ex | 35,000 | 2.86 | 100,065 |
| 2007-05-02 | Yang Taiyin (SVP, Pharm Dev & Mfg) | Sale | 20,000 | 83.77 | 1,675,300 |
| 2007-05-02 | Lee William A (SVP, Research) | Sale | 95,000 | 83.25 | 7,908,750 |
| 2007-05-02 | Lee William A (SVP, Research) | Option Ex | 95,000 | 16.44 | 1,561,515 |
| 2007-05-02 | Bischofberger Norbert W (EVP, Research) | Sale | 120,000 | 83.87 | 10,064,640 |
| 2007-05-02 | Bischofberger Norbert W (EVP, Research) | Option Ex | 120,000 | 17.89 | 2,146,200 |
| 2007-05-01 | Alton Gregg H (SVP, General Counsel) | Sale | 4,750 | 82.33 | 391,043 |
| 2007-05-01 | Alton Gregg H (SVP, General Counsel) | Option Ex | 4,750 | 16.44 | 78,075 |
| 2007-05-01 | Berg Paul | Sale | 3,750 | 82.24 | 308,407 |
| 2007-05-01 | Berg Paul | Option Ex | 3,750 | 5.41 | 20,272 |
| 2007-04-30 | Berg Paul | Sale | 3,750 | 81.36 | 305,085 |
| 2007-04-30 | Berg Paul | Option Ex | 3,750 | 5.41 | 20,272 |
| 2007-04-25 | Toole John J (SVP, Clinical Research) | Sale | 19,148 | 83.09 | 1,591,103 |
| 2007-04-25 | Toole John J (SVP, Clinical Research) | Option Ex | 19,148 | 13.60 | 260,451 |
| 2007-04-24 | Meyers James R (SVP Comm Ops North America) | Sale | 9,000 | 83.17 | 748,557 |
| 2007-04-24 | Meyers James R (SVP Comm Ops North America) | Option Ex | 9,000 | 7.40 | 66,582 |
| 2007-04-24 | Hills Carla A | Buy | 121 | 83.20 | 10,067 |
| 2007-04-23 | Lee William A (SVP, Research) | Sale | 92,796 | 83.04 | 7,708,750 |
| 2007-04-23 | Lee William A (SVP, Research) | Option Ex | 92,796 | 10.78 | 1,000,619 |
| 2007-04-19 | Alton Gregg H (SVP, General Counsel) | Sale | 14,500 | 80.00 | 1,160,000 |
| 2007-04-19 | Alton Gregg H (SVP, General Counsel) | Option Ex | 14,500 | 17.16 | 248,849 |
| 2007-04-10 | Martin John C (President and CEO) | Sale | 35,000 | 78.14 | 2,734,970 |
| 2007-04-10 | Martin John C (President and CEO) | Option Ex | 35,000 | 2.86 | 100,065 |
| 2007-04-02 | Alton Gregg H (SVP, General Counsel) | Sale | 4,750 | 76.42 | 362,971 |
| 2007-04-02 | Alton Gregg H (SVP, General Counsel) | Option Ex | 4,750 | 17.16 | 81,519 |
| 2007-03-23 | Alton Gregg H (SVP, General Counsel) | Sale | 30,200 | 75.00 | 2,265,000 |
| 2007-03-23 | Alton Gregg H (SVP, General Counsel) | Option Ex | 20,200 | 15.38 | 310,716 |
| 2007-03-14 | Berg Paul | Sale | 6,500 | 68.83 | 447,401 |
| 2007-03-14 | Berg Paul | Option Ex | 6,500 | 4.78 | 31,076 |
| 2007-03-13 | Martin John C (President and CEO) | Sale | 35,000 | 70.26 | 2,458,960 |
| 2007-03-13 | Martin John C (President and CEO) | Option Ex | 35,000 | 2.86 | 100,065 |
| 2007-03-06 | Denny James M | Sale | 30,000 | 70.62 | 2,116,514 |
| 2007-03-06 | Denny James M | Option Ex | 40,000 | 5.68 | 227,079 |
| 2007-03-01 | Alton Gregg H (SVP, General Counsel) | Sale | 4,750 | 70.21 | 333,497 |
| 2007-03-01 | Alton Gregg H (SVP, General Counsel) | Option Ex | 4,750 | 13.60 | 64,609 |
| 2007-02-28 | Meyers James R (SVP Comm Ops North America) | Sale | 6,000 | 71.35 | 428,088 |
| 2007-02-28 | Meyers James R (SVP Comm Ops North America) | Option Ex | 6,000 | 8.21 | 49,266 |
| 2007-02-23 | Toole John J (SVP, Clinical Research) | Sale | 20,000 | 73.27 | 1,465,420 |
| 2007-02-23 | Toole John J (SVP, Clinical Research) | Option Ex | 20,000 | 13.60 | 272,040 |
| 2007-02-22 | Milligan John F (EVP, Chief Financial Officer) | Sale | 20,000 | 73.63 | 1,472,620 |
| 2007-02-22 | Milligan John F (EVP, Chief Financial Officer) | Option Ex | 20,000 | 8.60 | 172,079 |
| 2007-02-21 | Yang Taiyin (SVP, Pharm Dev & Mfg) | Sale | 20,000 | 73.74 | 1,474,820 |
| 2007-02-21 | Moore Gordon Earle | Option Ex | 16,000 | 3.28 | 52,496 |
| 2007-02-20 | Young Kevin (EVP, Commercial Operations) | Sale | 30,000 | 72.30 | 2,168,880 |
| 2007-02-20 | Young Kevin (EVP, Commercial Operations) | Option Ex | 30,000 | 33.69 | 1,010,550 |
| 2007-02-16 | Lee William A (SVP, Research) | Sale | 32,000 | 72.00 | 2,303,840 |
| 2007-02-16 | Lee William A (SVP, Research) | Option Ex | 32,000 | 7.41 | 236,992 |
| 2007-02-15 | Lee William A (SVP, Research) | Sale | 20,000 | 72.03 | 1,440,660 |
| 2007-02-15 | Lee William A (SVP, Research) | Option Ex | 20,000 | 7.41 | 148,120 |
| 2007-02-13 | Martin John C (President and CEO) | Sale | 35,000 | 70.88 | 2,480,940 |
| 2007-02-13 | Martin John C (President and CEO) | Option Ex | 35,000 | 2.86 | 100,065 |
| 2007-02-09 | Bischofberger Norbert W (EVP, Research) | Sale | 133,920 | 71.27 | 9,544,478 |
| 2007-02-09 | Bischofberger Norbert W (EVP, Research) | Option Ex | 140,000 | 16.44 | 2,301,180 |
| 2007-02-06 | Yang Taiyin (SVP, Pharm Dev & Mfg) | Sale | 20,000 | 70.23 | 1,404,600 |
| 2007-02-06 | Davignon Etienne | Sale | 19,000 | 69.95 | 1,329,068 |
| 2007-02-01 | Alton Gregg H (SVP, General Counsel) | Sale | 20,650 | 70.38 | 1,453,243 |
| 2007-02-01 | Alton Gregg H (SVP, General Counsel) | Option Ex | 20,650 | 13.60 | 280,881 |
| 2007-01-10 | Berg Paul | Sale | 6,500 | 64.42 | 418,704 |
| 2007-01-10 | Berg Paul | Option Ex | 6,500 | 4.78 | 31,076 |
| 2007-01-09 | Martin John C (President and CEO) | Sale | 35,000 | 65.34 | 2,286,865 |
| 2007-01-09 | Martin John C (President and CEO) | Option Ex | 35,000 | 2.86 | 100,065 |
| 2007-01-03 | Alton Gregg H (SVP, General Counsel) | Sale | 3,550 | 64.49 | 228,950 |
| 2007-01-03 | Alton Gregg H (SVP, General Counsel) | Option Ex | 3,550 | 13.60 | 48,287 |
| 2006-12-20 | Toole John J (SVP, Clinical Research) | Option Ex | 4,000 | 7.40 | 29,592 |
| 2006-12-20 | Milligan John F (EVP, Chief Financial Officer) | Option Ex | 4,060 | 7.08 | 28,736 |
| 2006-12-12 | Martin John C (President and CEO) | Sale | 35,000 | 65.51 | 2,292,745 |
| 2006-12-12 | Martin John C (President and CEO) | Option Ex | 35,000 | 2.86 | 100,065 |
| 2006-12-04 | Alton Gregg H (SVP, General Counsel) | Sale | 1,200 | 67.00 | 80,400 |
| 2006-12-04 | Alton Gregg H (SVP, General Counsel) | Option Ex | 1,200 | 13.60 | 16,322 |
| 2006-12-01 | Alton Gregg H (SVP, General Counsel) | Sale | 3,550 | 65.12 | 231,176 |
| 2006-12-01 | Alton Gregg H (SVP, General Counsel) | Option Ex | 3,550 | 13.60 | 48,287 |
| 2006-11-22 | Lee William A (SVP, Research) | Option Ex | 20,000 | 3.27 | 65,300 |
| 2006-11-20 | Alton Gregg H (SVP, General Counsel) | Sale | 100 | 70.00 | 7,000 |
| 2006-11-20 | Alton Gregg H (SVP, General Counsel) | Option Ex | 100 | 13.60 | 1,360 |
| 2006-11-17 | Toole John J (SVP, Clinical Research) | Sale | 36,328 | 68.96 | 2,505,287 |
| 2006-11-17 | Toole John J (SVP, Clinical Research) | Option Ex | 36,528 | 10.30 | 376,347 |
| 2006-11-17 | Moore Nicholas G | Sale | 30,020 | 68.42 | 2,059,687 |
| 2006-11-17 | Moore Nicholas G | Option Ex | 30,000 | 26.73 | 801,900 |
| 2006-11-14 | Martin John C (President and CEO) | Sale | 35,000 | 66.66 | 2,333,240 |
| 2006-11-14 | Martin John C (President and CEO) | Option Ex | 35,000 | 2.86 | 100,065 |
| 2006-11-08 | Berg Paul | Sale | 6,500 | 69.41 | 451,178 |
| 2006-11-08 | Berg Paul | Option Ex | 6,500 | 4.78 | 31,076 |
| 2006-11-08 | Denny James M | Sale | 30,000 | 68.72 | 2,061,569 |
| 2006-11-08 | Denny James M | Option Ex | 40,000 | 5.13 | 205,280 |
| 2006-11-01 | Alton Gregg H (SVP, General Counsel) | Sale | 4,750 | 68.28 | 323,978 |
| 2006-11-01 | Alton Gregg H (SVP, General Counsel) | Option Ex | 4,750 | 13.60 | 64,609 |
| 2006-10-30 | Milligan John F (EVP, Chief Financial Officer) | Sale | 30,000 | 68.71 | 2,061,389 |
| 2006-10-30 | Milligan John F (EVP, Chief Financial Officer) | Option Ex | 30,000 | 7.40 | 221,940 |
| 2006-10-27 | Davignon Etienne | Option Ex | 40,000 | 3.12 | 125,000 |
| 2006-10-26 | Lee William A (SVP, Research) | Sale | 61,000 | 69.11 | 4,215,954 |
| 2006-10-26 | Lee William A (SVP, Research) | Option Ex | 61,000 | 7.40 | 451,278 |
| 2006-10-25 | Bischofberger Norbert W (EVP, Research) | Sale | 140,000 | 67.73 | 9,501,879 |
| 2006-10-25 | Bischofberger Norbert W (EVP, Research) | Option Ex | 140,000 | 17.89 | 2,503,900 |
| 2006-10-24 | Davignon Etienne | Sale | 2,000 | 68.82 | 137,632 |
| 2006-10-24 | Lee William A (SVP, Research) | Sale | 23,000 | 69.25 | 1,592,750 |
| 2006-10-24 | Lee William A (SVP, Research) | Option Ex | 23,000 | 7.40 | 170,154 |
| 2006-10-23 | Lee William A (SVP, Research) | Sale | 30,000 | 69.37 | 2,081,190 |
| 2006-10-23 | Lee William A (SVP, Research) | Option Ex | 30,000 | 7.40 | 221,940 |
| 2006-10-19 | Moore Gordon Earle | Option Ex | 56,000 | 3.12 | 175,000 |
| 2006-10-12 | Alton Gregg H (SVP, General Counsel) | Sale | 1,200 | 67.00 | 80,400 |
| 2006-10-12 | Alton Gregg H (SVP, General Counsel) | Option Ex | 1,200 | 13.60 | 16,322 |
| 2006-10-10 | Martin John C (President and CEO) | Sale | 35,000 | 64.50 | 2,257,640 |
| 2006-10-10 | Martin John C (President and CEO) | Option Ex | 35,000 | 2.86 | 100,065 |
| 2006-10-02 | Alton Gregg H (SVP, General Counsel) | Sale | 3,550 | 64.96 | 230,597 |
| 2006-10-02 | Alton Gregg H (SVP, General Counsel) | Option Ex | 3,550 | 13.60 | 48,287 |
| 2006-09-27 | Alton Gregg H (SVP, General Counsel) | Sale | 2,400 | 67.00 | 160,800 |
| 2006-09-27 | Alton Gregg H (SVP, General Counsel) | Option Ex | 1,112 | 13.60 | 15,125 |
| 2006-09-13 | Berg Paul | Sale | 6,500 | 63.45 | 412,392 |
| 2006-09-13 | Berg Paul | Option Ex | 6,500 | 4.78 | 31,076 |
| 2006-09-12 | Martin John C (President and CEO) | Sale | 35,000 | 62.85 | 2,199,610 |
| 2006-09-12 | Martin John C (President and CEO) | Option Ex | 35,000 | 2.86 | 100,065 |
| 2006-09-01 | Alton Gregg H (SVP, General Counsel) | Sale | 3,550 | 63.56 | 225,638 |
| 2006-08-17 | Alton Gregg H (SVP, General Counsel) | Sale | 3,550 | 64.25 | 228,080 |
| 2006-08-16 | Toole John J (SVP, Clinical Research) | Sale | 51,432 | 63.74 | 3,278,332 |
| 2006-08-16 | Toole John J (SVP, Clinical Research) | Option Ex | 50,000 | 8.60 | 430,199 |
| 2006-08-09 | Young Kevin (EVP, Commercial Operations) | Sale | 24,000 | 62.03 | 1,488,720 |
| 2006-08-09 | Young Kevin (EVP, Commercial Operations) | Option Ex | 24,000 | 32.02 | 768,480 |
| 2006-08-09 | Lee William A (SVP, Research) | Sale | 53,896 | 62.58 | 3,372,811 |
| 2006-08-09 | Lee William A (SVP, Research) | Option Ex | 53,896 | 7.30 | 393,225 |
| 2006-08-09 | Denny James M | Sale | 60,000 | 62.05 | 3,725,544 |
| 2006-08-09 | Denny James M | Option Ex | 80,000 | 4.96 | 396,560 |
| 2006-08-08 | Lee William A (SVP, Research) | Sale | 30,000 | 61.91 | 1,857,300 |
| 2006-08-08 | Lee William A (SVP, Research) | Option Ex | 30,000 | 7.30 | 218,880 |
| 2006-08-01 | Martin John C (President and CEO) | Sale | 120,000 | 60.57 | 7,268,520 |
| 2006-08-01 | Martin John C (President and CEO) | Option Ex | 120,000 | 3.06 | 367,440 |
| 2006-08-01 | Bischofberger Norbert W (EVP, Research) | Sale | 120,000 | 60.51 | 7,260,840 |
| 2006-08-01 | Bischofberger Norbert W (EVP, Research) | Option Ex | 120,000 | 16.44 | 1,972,440 |
| 2006-07-25 | Alton Gregg H (SVP, General Counsel) | Sale | 5,000 | 62.00 | 310,000 |
| 2006-07-25 | Milligan John F (EVP, Chief Financial Officer) | Sale | 60,000 | 60.84 | 3,650,100 |
| 2006-07-25 | Milligan John F (EVP, Chief Financial Officer) | Option Ex | 60,000 | 9.58 | 574,680 |
| 2006-07-12 | Berg Paul | Sale | 6,500 | 61.66 | 400,261 |
| 2006-07-12 | Berg Paul | Option Ex | 6,500 | 4.78 | 31,076 |
| 2006-06-23 | Alton Gregg H (SVP, General Counsel) | Option Ex | 2,788 | 11.44 | 31,883 |
| 2006-05-18 | Martin John C (President and CEO) | Option Ex | 39,936 | 2.86 | 114,176 |
| 2006-05-17 | Bischofberger Norbert W (EVP, Research) | Sale | 100,000 | 55.64 | 5,563,900 |
| 2006-05-17 | Bischofberger Norbert W (EVP, Research) | Option Ex | 100,000 | 16.44 | 1,643,700 |
| 2006-05-15 | Martin John C (President and CEO) | Sale | 120,000 | 57.05 | 6,846,000 |
| 2006-05-15 | Martin John C (President and CEO) | Option Ex | 120,000 | 3.27 | 391,800 |
| 2006-05-10 | Berg Paul | Sale | 6,500 | 57.27 | 372,268 |
| 2006-05-10 | Berg Paul | Option Ex | 6,500 | 4.78 | 31,076 |
| 2006-05-10 | Denny James M | Sale | 30,000 | 57.65 | 1,729,440 |
| 2006-05-10 | Denny James M | Option Ex | 40,000 | 4.78 | 191,240 |
| 2006-04-28 | Lee William A (SVP, Research) | Option Ex | 10,000 | 3.27 | 32,650 |
| 2006-03-08 | Berg Paul | Sale | 6,500 | 59.18 | 384,676 |
| 2006-03-08 | Berg Paul | Option Ex | 6,500 | 4.78 | 31,076 |
| 2006-03-06 | Alton Gregg H (SVP, General Counsel) | Option Ex | 14,894 | 9.42 | 140,286 |
| 2006-03-06 | Denny James M | Sale | 30,000 | 59.75 | 1,792,560 |
| 2006-03-06 | Denny James M | Option Ex | 40,000 | 3.95 | 158,120 |
| 2006-02-22 | Yang Taiyin (SVP, Pharm Dev & Mfg) | Sale | 20,000 | 61.20 | 1,223,920 |
| 2006-02-16 | Martin John C (President and CEO) | Sale | 120,000 | 61.73 | 7,407,840 |
| 2006-02-16 | Martin John C (President and CEO) | Option Ex | 120,000 | 3.27 | 391,800 |
| 2006-02-15 | Lee William A (SVP, Research) | Sale | 20,000 | 60.88 | 1,217,500 |
| 2006-02-14 | Lee William A (SVP, Research) | Sale | 30,000 | 60.25 | 1,807,500 |
| 2006-02-14 | Bischofberger Norbert W (EVP, Research) | Sale | 136,488 | 59.13 | 8,070,262 |
| 2006-02-14 | Bischofberger Norbert W (EVP, Research) | Option Ex | 136,488 | 11.92 | 1,626,663 |
| 2006-02-13 | Yang Taiyin (SVP, Pharm Dev & Mfg) | Option Ex | 99,046 | 8.38 | 830,500 |
| 2006-02-13 | Bischofberger Norbert W (EVP, Research) | Option Ex | 13,512 | 7.40 | 99,961 |
| 2006-02-09 | Toole John J (SVP, Clinical Research) | Sale | 35,472 | 59.42 | 2,107,639 |
| 2006-02-09 | Toole John J (SVP, Clinical Research) | Option Ex | 35,472 | 10.55 | 374,229 |
| 2006-02-08 | Lee William A (SVP Research and PPD) | Sale | 10,000 | 60.50 | 605,000 |
| 2006-02-07 | Lee William A (SVP Research and PPD) | Sale | 40,000 | 60.21 | 2,408,400 |
| 2006-02-07 | Lee William A (SVP Research and PPD) | Option Ex | 10,000 | 7.30 | 72,970 |
| 2006-02-06 | Milligan John F (EVP, Chief Financial) | Sale | 30,000 | 60.57 | 1,817,040 |
| 2006-02-06 | Milligan John F (EVP, Chief Financial) | Option Ex | 30,000 | 11.76 | 352,740 |
| 2006-02-03 | Young Kevin (EVP, Commercial Oper) | Sale | 25,000 | 61.21 | 1,530,350 |
| 2006-02-03 | Young Kevin (EVP, Commercial Oper) | Option Ex | 25,000 | 33.69 | 842,125 |
| 2006-02-02 | Alton Gregg H (SVP, General Counsel) | Sale | 10,000 | 60.24 | 602,450 |
| 2006-02-02 | Young Kevin (EVP, Commercial Oper) | Sale | 50,000 | 60.41 | 3,020,600 |
| 2005-12-23 | Toole John J (SVP, Clinical Resear) | Option Ex | 3,800 | 8.21 | 31,201 |
| 2005-12-23 | Milligan John F (EVP, Chief Financial) | Option Ex | 5,500 | 7.19 | 39,534 |
| 2005-11-22 | Yang Taiyin (Mfg) | Sale | 20,000 | 54.02 | 1,080,360 |
| 2005-11-22 | Berg Paul | Sale | 6,000 | 54.50 | 327,000 |
| 2005-08-31 | Yang Taiyin (Mfg) | Sale | 10,000 | 42.11 | 421,100 |
| 2005-05-27 | Lee William A (SVP Research and PPD) | Sale | 20,000 | 41.08 | 821,500 |
| 2005-05-10 | Caracciolo Anthony (SVP) | Sale | 5,518 | 38.85 | 214,390 |
| 2005-05-04 | Shultz George P | Sale | 124,480 | 39.38 | 4,891,600 |
Insider trading activities including stock purchases, stock sales, and option exercises of GILD listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Gilead Sciences Inc (symbol GILD, CIK number 882095) see the Securities and Exchange Commission (SEC) website.